Aquinox Pharmaceuticals Inc. (Nasdaq: AQXP) reported disappointing results
from a Phase 2 FLAGSHIP clinical trial with AQX-1125 in patients with
chronic obstructive pulmonary disease sending the stock price plummeting $4.53 to $2.01.
Aquinox Pharmaceuticals reports disappointing trial results
July 09, 2015 at 13:13 PM EDT
